OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
MIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has...
MIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has...
Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very...
Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat Improves Predictive...
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease...
ORANGE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Medicare Advantage company Alignment Healthcare (NASDAQ: ALHC) today announced a significant expansion...
Company will underscore the importance of rapid diagnostic technology for detecting bloodstream infections (BSIs) and sepsisLEXINGTON, Mass., June 21, 2021...
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next...
Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe’s Board as the Company Sets to Accelerate Personalized Healthcare Based on...
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep...
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include...
ORANGE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Medicare Advantage company Alignment Healthcare (NASDAQ: ALHC) today announced the expansion of...
SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a company focused on cellular and cell-derived therapeutics for...
Data presented at the 16th ICML Meeting demonstrate KT-413’s potent antitumor activity as a monotherapy compared to a clinically active...
NewYorkBIO and NYSE’s Emerging Biotech Company ShowcaseSpring European Virtual MidCap Event31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2021)Epigenetic...
SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of...
New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBCNEWARK, Calif.,...
New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in...
Sydney, AUSTRALIA, June 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to...
CX-2029 is the first CD71-targeting antibody-drug conjugate (ADC) administrated to patients, with a generally well-tolerated safety profile at doses that...
New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumoursExpands the evaluation of efti into a triple...